Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

A humanized IgG4 anti–HLA-DR monoclonal antibody (IMMU-114), engineered to avoid side effects associated with complement activation, was examined for binding and cytotoxicity on leukemia, lymphoma, and multiple myeloma cell lines and chronic lymphocytic leukemia (CLL) patient specimens, followed by...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stein, Rhona, Gupta, Pankaj, Chen, Xiaochuan, Cardillo, Thomas M., Furman, Richard R., Chen, Susan, Chang, Chien-Hsing, Goldenberg, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2892948/
https://ncbi.nlm.nih.gov/pubmed/20101022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-06-228288
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados